艾沙康唑的治疗药物监测——那重症患者呢？
Therapeutic Drug Monitoring of Isavuconazole-But What about the Critically Ill?
作者信息
Salhotra Ripenmeet
机构信息
Department of Critical Care Medicine, Amrita Hospital, Faridabad, Hayana, India.
出版信息
Indian J Crit Care Med. 2023 Jun;27(6):454-455. doi: 10.5005/jp-journals-10071-24450.
Abstract
UNLABELLED
Data on therapeutic drug monitoring of novel, broad-spectrum, and promising antifungal agent Isavuconazole sheds light on factors associated with subtherapeutic drug levels, however, a few other parameters, which characterize the critically ill patients, if included in the analysis, would have improved the understanding of drugs pharmacokinetics in this subset.
HOW TO CITE THIS ARTICLE
Salhotra R. Therapeutic Drug Monitoring of Isavuconazole-But What about the Critically Ill? Indian J Crit Care Med 2023;27(6):454-455.
摘要
未标注
关于新型、广谱且有前景的抗真菌药物艾沙康唑的治疗药物监测数据揭示了与药物水平低于治疗剂量相关的因素，然而，如果在分析中纳入一些其他表征重症患者的参数，将有助于更好地理解该亚组患者的药物药代动力学。
如何引用本文
Salhotra R. 艾沙康唑的治疗药物监测——但重症患者呢？《印度重症监护医学杂志》2023年；27(6):454 - 455。
相似文献
1
Therapeutic Drug Monitoring of Isavuconazole-But What about the Critically Ill?艾沙康唑的治疗药物监测——那重症患者呢？
Indian J Crit Care Med. 2023 Jun;27(6):454-455. doi: 10.5005/jp-journals-10071-24450.
2
Therapeutic Drug Monitoring of Isavuconazole: Lessons Learnt from a Real-life Setting in a Tertiary Care Center in India.艾沙康唑的治疗药物监测：从印度一家三级医疗中心的实际情况中吸取的经验教训。
Indian J Crit Care Med. 2023 Apr;27(4):260-264. doi: 10.5005/jp-journals-10071-24443.
3
Isavuconazole therapeutic drug monitoring in critically ill ICU patients: A monocentric retrospective analysis.重症监护病房危重症患者伊曲康唑治疗药物监测：一项单中心回顾性分析。
Mycoses. 2022 Jul;65(7):747-752. doi: 10.1111/myc.13469. Epub 2022 May 31.
4
Lower blood levels of isavuconazole in critically ill patients compared with other populations: possible need for therapeutic drug monitoring.与其他人群相比，危重症患者的伊曲康唑血药浓度较低：可能需要治疗药物监测。
J Antimicrob Chemother. 2024 Apr 2;79(4):835-845. doi: 10.1093/jac/dkae037.
5
Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.危重患者中艾沙康唑的药代动力学：与临床疗效和患者安全性的关系。
Antibiotics (Basel). 2024 Jul 29;13(8):706. doi: 10.3390/antibiotics13080706.
6
Author Reply: Therapeutic Drug Monitoring of Isavuconazole: Lessons Learnt from a Real-life Setting in a Tertiary Care Center in India.作者回复：艾沙康唑的治疗药物监测：从印度一家三级护理中心的实际情况中吸取的经验教训。
Indian J Crit Care Med. 2023 Jun;27(6):451. doi: 10.5005/jp-journals-10071-24471.
7
Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies.群体药代动力学研究：危重症患者中异康唑及其游离药物的药动学特征及其对适应性给药策略的影响。
Clin Pharmacokinet. 2023 Dec;62(12):1701-1711. doi: 10.1007/s40262-023-01305-8. Epub 2023 Oct 11.
8
Clinical and demographic factors affecting trough levels of isavuconazole in critically ill patients with or without COVID-19.影响 COVID-19 患者和非 COVID-19 患者的重症患者伊曲康唑谷浓度的临床和人口统计学因素。
Mycoses. 2023 Dec;66(12):1071-1078. doi: 10.1111/myc.13653. Epub 2023 Sep 12.
9
Isavuconazole Exposure in Critically Ill Patients Treated with Extracorporeal Membrane Oxygenation: Two Case Reports and a Narrative Literature Review.接受体外膜肺氧合治疗的重症患者的艾沙康唑暴露情况：两例病例报告及文献综述
Antibiotics (Basel). 2023 Jun 21;12(7):1085. doi: 10.3390/antibiotics12071085.
10
A simple high performance liquid chromatography-mass spectrometry method for Therapeutic Drug Monitoring of isavuconazole and four other antifungal drugs in human plasma samples.一种用于监测人血浆样本中艾沙康唑及其他四种抗真菌药物治疗药物浓度的简单高效液相色谱 - 质谱法。
J Pharm Biomed Anal. 2017 Oct 25;145:718-724. doi: 10.1016/j.jpba.2017.07.040. Epub 2017 Aug 5.
本文引用的文献
1
Therapeutic Drug Monitoring of Isavuconazole: Lessons Learnt from a Real-life Setting in a Tertiary Care Center in India.艾沙康唑的治疗药物监测：从印度一家三级医疗中心的实际情况中吸取的经验教训。
Indian J Crit Care Med. 2023 Apr;27(4):260-264. doi: 10.5005/jp-journals-10071-24443.
2
Population Pharmacokinetics of Isavuconazole in Critical Care Patients with COVID-19-Associated Pulmonary Aspergillosis and Monte Carlo Simulations of High Off-Label Doses.艾沙康唑在新冠病毒相关肺曲霉病重症监护患者中的群体药代动力学及高超说明书剂量的蒙特卡洛模拟
J Fungi (Basel). 2023 Feb 6;9(2):211. doi: 10.3390/jof9020211.
3
Pharmacokinetics in sepsis.脓毒症中的药代动力学
BJA Educ. 2019 Jan;19(1):7-13. doi: 10.1016/j.bjae.2018.09.006. Epub 2018 Nov 9.
4
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.伊曲康唑与伏立康唑治疗曲霉菌和其他丝状真菌所致侵袭性霉菌病的初步治疗（SECURE）：一项 3 期随机对照非劣效性试验。
Lancet. 2016 Feb 20;387(10020):760-9. doi: 10.1016/S0140-6736(15)01159-9. Epub 2015 Dec 10.
Zotero 插件